Skip to main content
Premium Trial:

Request an Annual Quote

Bioanalytical Instrumentation Firm Creoptix Raises CHF 8M

NEW YORK — Creoptix, a Swiss developer of optical bioanalytic instrumentation, said today that it has raised CHF 8 million ($8.0 million) in a Series C financing round.

The round was led by Zürcher Kantonalbank's Swisscanto Invest and included existing investor Waters. In connection with the round, Swisscanto Invest has received a seat on Creoptix's board of directors.

Creoptix markets the waveguide interferometry-based WAVE system for studying molecular interactions in real time, with applications in membrane protein analysis in drug discovery and kinetic interaction studies in body fluids for biomarker and biotherapeutics development. The company said it will use the financing to bolster its commercial operations in Europe and the US, as well as to expand into new markets.

Creoptix said it has raised CHF 15 million since 2013.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.